Inactive Instrument

Sierra Oncology, Inc.

SRRA

US82640U4040

Biotechnology & Medical Research

ProNAi Therapeutics, Inc. Announces the Resignation of Wendi Rodrigueza as Chief Scientific Officer, Effective February 25, 2016

January 29, 2016 at 04:10 pm

On January 25, 2016, Wendi Rodrigueza notified ProNAi Therapeutics, Inc. of her decision to resign as the company's Chief Scientific Officer, effective February 25, 2016.

Latest news about Sierra Oncology, Inc.

Sierra Oncology, Inc. Announces Update on Sra737	23-03-06	CI
Sareum Holdings Says GSK Completes Acquisition of Sierra Oncology	22-07-04	DJ
Sierra Oncology, Inc.(NasdaqGM:SRRA) dropped from NASDAQ Composite Index	22-07-04	CI
Sierra Oncology, Inc. Announces Executive Changes	22-07-01	CI
GSK Completes $1.9 Billion Purchase of Sierra Oncology	22-07-01	MT
GlaxoSmithKline plc completed the acquisition of Sierra Oncology, Inc. from Frazier Healthcare VI, L.P., Frazier Life Sciences VIII, L.P., Frazier Life Sciences Public Fund, L.P., all managed by Frazier Management, L.L.C., and others.	22-06-30	CI
Sierra Oncology Shareholders Approve Acquisition by GSK	22-06-29	MT
Sierra Oncology, Inc.(NasdaqGM:SRRA) added to Russell 2500 Index	22-06-24	CI
Sierra Oncology, Inc.(NasdaqGM:SRRA) added to Russell 2500 Growth Index	22-06-24	CI
Sierra Oncology, Inc.(NasdaqGM:SRRA) added to Russell Small Cap Completeness Index	22-06-24	CI
Sierra Oncology, Inc.(NasdaqGM:SRRA) added to Russell 3000 Index	22-06-24	CI
Sierra Oncology, Inc.(NasdaqGM:SRRA) added to Russell 3000E Growth Index	22-06-24	CI
Sierra Oncology, Inc.(NasdaqGM:SRRA) dropped from Russell 3000E Value Index	22-06-24	CI
Sierra Oncology, Inc.(NasdaqGM:SRRA) added to Russell 3000E Index	22-06-24	CI
Sierra Oncology, Inc.(NasdaqGM:SRRA) added to Russell Small Cap Comp Growth Index	22-06-24	CI
Sierra Oncology, Inc.(NasdaqGM:SRRA) added to Russell 2000 Growth Index	22-06-24	CI
Sierra Oncology, Inc.(NasdaqGM:SRRA) added to Russell 2000 Index	22-06-24	CI
Sierra Oncology, Inc.(NasdaqGM:SRRA) added to Russell 2000 Dynamic Index	22-06-24	CI
Sierra Oncology, Inc.(NasdaqGM:SRRA) added to Russell 3000 Growth Index	22-06-24	CI
Sierra Oncology, Inc.(NasdaqGM:SRRA) dropped from Russell Microcap Value Index	22-06-24	CI
Sierra Oncology Submits New Drug Application to FDA for Cancer Treatment Momelotinib	22-06-17	MT
Sierra Oncology, Inc. Announces Submission of New Drug Application for Momelotinib to US Food & Drug Administration	22-06-17	CI
Pfizer to sell stake in GSK's consumer health business after it lists	22-06-01	RE
GSK to spend up to $3.3 bln on Affinivax to boost vaccines roster	22-05-31	RE
Sierra Oncology, Inc. Announces Momelotinib Pivotal Phase 3 Data Receives Oral Presentation At American Society of Clinical Oncology Annual Meeting	22-05-26	CI

Sierra Oncology, Inc. is late stage drug development company. The Company is focused on advancing targeted therapeutics for the treatment of patients with unmet medical needs in hematology and oncology. Momelotinib, the Company's lead drug candidate, is a potent, selective and orally-bioavailable janus kinase one (JAK1), janus kinase two (JAK2) and activin a receptor type one (ACVR1) inhibitor with a differentiated therapeutic profile in myelofibrosis. The Company is also developing a portfolio of deoxyribonucleic acid (DNA) damage response (DDR) assets, consisting of SRA737 and SRA141. SRA737 is a potent, selective, orally bioavailable small molecule inhibitor of checkpoint kinase 1 (Chk1), a key regulator of cell cycle progression and the DDR network. SRA141 is a potent, selective, orally bioavailable small molecule inhibitor of Cell division cycle 7 kinase (Cdc7).

Sector

Biotechnology & Medical Research

More about the company

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
VERTEX PHARMACEUTICALS INCORPORATED	+16.13%	122B
REGENERON PHARMACEUTICALS, INC.	+19.65%	113B
ARGENX SE	+21.22%	26.49B
BIONTECH SE	-23.84%	19.4B
GENMAB A/S	-17.47%	16.24B
WUXI APPTEC CO., LTD.	-45.95%	15.15B
BEIGENE, LTD.	-19.28%	15.4B
SAREPTA THERAPEUTICS, INC.	+63.81%	14.93B
NEUROCRINE BIOSCIENCES, INC.	+1.94%	13.52B

Bio Therapeutic Drugs

Sierra Oncology, Inc.

Equities

SRRA

US82640U4040

Biotechnology & Medical Research

ProNAi Therapeutics, Inc. Announces the Resignation of Wendi Rodrigueza as Chief Scientific Officer, Effective February 25, 2016

Latest news about Sierra Oncology, Inc.

Chart Sierra Oncology, Inc.

Company Profile

Sector Bio Therapeutic Drugs